Modulation of transthyretin expression
US11535849B2 · kind B2 · utility
0Cited by
244References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 1, 2020 |
| Grant date | Dec 27, 2022 |
| Priority date | — |
| Expiry date | Jun 1, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.